Recurrent Glioblastoma Multiforme Clinical Trial
Immunotoxins can locate tumor cells and kill them without harming normal cells. Immunotoxin therapy may be effective in treating malignant glioma.
n/a
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00597493 -
Ph. 2 Sorafenib + Protracted Temozolomide in Recurrent GBM
|
Phase 2 | |
| Completed |
NCT00379470 -
Effect of NovoTTF-100A in Recurrent Glioblastoma Multiforme (GBM)
|
Phase 3 | |
| Recruiting |
NCT01737346 -
Procarbazine and Lomustine in Recurrent Glioblastoma
|
Phase 2 | |
| Active, not recruiting |
NCT01464177 -
Hypofractionated Stereotactic Radiotherapy in Recurrent Glioblastoma Multiforme
|
Phase 2 | |
| Active, not recruiting |
NCT00562419 -
CT-322 in Treating Patients With Recurrent Glioblastoma Multiforme and Combination Therapy With Irinotecan
|
Phase 2 | |
| Active, not recruiting |
NCT02062827 -
Genetically Engineered HSV-1 Phase 1 Study for the Treatment of Recurrent Malignant Glioma
|
Phase 1 | |
| Completed |
NCT00509301 -
Safety & Radiation Distribution Study of Cotara® in Patients With Recurrent Glioblastoma Multiforme
|
Phase 1 | |
| Recruiting |
NCT05868083 -
The Safety and Efficacy of SNC-109 CAR-T Cells Therapy the Recurrent Glioblastoma
|
Phase 1 | |
| Completed |
NCT01576666 -
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
|
Phase 1 | |
| Completed |
NCT01738646 -
Ph II SAHA and Bevacizumab for Recurrent Malignant Glioma Patients
|
Phase 2 | |
| Completed |
NCT00306618 -
Safety and Efficacy Study of Panzem NCD to Treat Glioblastoma
|
Phase 2 | |
| Completed |
NCT01934361 -
Phase Ib/II Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme
|
Phase 1 | |
| Recruiting |
NCT04915404 -
Berubicin in Adult Patients With Recurrent Glioblastoma Multiforme (WHO Grade IV)
|
Phase 1/Phase 2 | |
| Terminated |
NCT01756729 -
Post-approval Study of NovoTTF-100A in Recurrent GBM Patients
|
Phase 4 | |
| Completed |
NCT00747253 -
Monteris AutoLITT™ FIM Safety Trial for Recurrent/Progressive Brain Tumors
|
Phase 1 | |
| Completed |
NCT00883298 -
Bi-weekly Temozolomide Plus Bevacizumab for Adult Patients With Recurrent Glioblastoma Multiforme
|
Phase 2 | |
| Completed |
NCT00481455 -
Phase 2 Study of Panzem Nanocrystal Colloidal Dispersion (NCD) in Combination With Fixed-Dose Temozolomide to Patients With Recurrent Glioblastoma Multiforme (GBM)
|
Phase 2 | |
| Recruiting |
NCT03423628 -
A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
|
Phase 1 | |
| Recruiting |
NCT04689087 -
A Prospective, Open-label, Single-arm Clinical Study
|
N/A |